NEW YORK - Axsome Therapeutics, Inc. (NASDAQ:AXSM), a $5.28 billion biopharmaceutical company with impressive 51% revenue ...

The U.S. Food and Drug Administration has approved Axsome Therapeutics' Symbravo (meloxicam and rizatriptan) for the acute ...

Many people use the terms ‘migraine’ and ‘headache’ interchangeably. This leads many people to believe that migraines are not ...

Jan 30 (Reuters) - The U.S. Food and Drug Administration has approved Axsome Therapeutics' (AXSM.O), opens new tab ... elimination of migraine pain compared with a placebo. The FDA had declined ...

Opens in a new tab or window The FDA approved an oral combination of meloxicam and rizatriptan (Symbravo) to treat adults with acute migraine with or without aura, Axsome Therapeutics announced.

Clinical trials demonstrated that a single dose of Symbravo provides rapid migraine relief, sustains efficacy for up to 48 hours, and reduces the need for rescue medication. The FDA has approved ...

The FDA approval of SYMBRAVO for the acute treatment of migraines provides a significant new treatment option for millions of Americans suffering from this debilitating condition. SYMBRAVO ...

FDA Approves ... an important new option which can quickly stop a migraine attack, keep it away, and allow patients to resume their normal activities, with just a single dose." Approval of ...

NEW YORK - Axsome Therapeutics ... announced the U.S. Food and Drug Administration (FDA) has approved SYMBRAVO®, a novel migraine treatment for adults. SYMBRAVO, which combines meloxicam and ...

(RTTNews) - Axsome Therapeutics, Inc. (AXSM) announced that the FDA ... The approval of SYMBRAVO offers a new treatment option for the estimated 39 million Americans suffering from migraine ...